



CLINICAL PRACTICE GUIDELINE

Guideline coverage includes NICU KEMH, NICU PMH and NETS WA

Pulmonary Haemorrhage

This document should be read in conjunction with the [Disclaimer](#)

This is better termed “haemorrhagic pulmonary oedema” and is dependent on the primary cause. It is a form of fulminant lung oedema with leakage of red cells and capillary filtrate into the lungs. It must be differentiated from occurrence of a small amount of blood being aspirated from the end of an ETT secondary to trauma. It represents the extreme end of the spectrum of pulmonary oedema in the neonate.

Associated Clinical Conditions

- Severe birth asphyxia.
- Rhesus haemolytic disease with hydrops/near hydrops.
- Left heart failure.
- Congenital heart disease.
- Sepsis.
- Hypothermia.
- Fluid overload.
- Oxygen toxicity.
- Haemostasis failure.
- Any pre-existing lung disease will worsen, as protein-rich fluid in the alveoli will inhibit surfactant function.

Clinical Presentation

The commonest clinical presentation is in an infant with severe RDS on IPPV in high oxygen and heart failure secondary to a large pulmonary blood flow from a PDA. It is also associated with surfactant therapy.

Symptoms

- Sudden deterioration.
- Copious bloody secretions from the infant’s airway either up the ETT or from the larynx and mouth if not already intubated.
- Usually there is hypotension.
- The infant may be pale and unresponsive.
- The outcome is dependent on the cause of the oedema. At the time of collapse, infants are susceptible to neurological damage and GMH/IVH. The mortality is significant, can be as high as 50% unless managed well.

Investigations



- Check Hb, coagulation screen.
- Check ABG, biochemistry.
- CXR: often shows a white-out.
- Look for sepsis.

Management

- Maintain blood pressure.
- Correct acidosis by ventilation or drug therapy.
- Fluid balance - consider fluid restriction, administer [Frusemide](#) 1-1.5 mg/kg.
- Sedate as needed.
- Use high PEEP - 6-7 cms (redistributes lung water back into the interstitial space, improving oxygenation and ventilation-perfusion balance). Consider alternative modes of ventilation; HFOV or HFJV which may enable the use of higher PEEP or MAP.
- Surfactant - may help to overcome protein inhibition of endogenous surfactant.
- Check for PDA - opening of symptomatic PDA. Consider medical treatment for PDA if neonate not requiring inhaled nitric oxide.
- Suction - be careful as may aggravate bleed.
- Manage coagulopathy.
- Sepsis - use or review antibiotics.

Related WNHS policies, procedures and guidelines

Neonatal Medication Protocol - [Frusemide](#)

Document owner:	Neonatal Coordinating Group		
Author / Reviewer:	Neonatal Coordinating Group		
Date first issued:	June 2006		
Last reviewed:	1 st January 2016	Next review date:	1 st January 2019
Endorsed by:	Neonatal Coordinating Group	Date endorsed:	January 2016
Standards Applicable:	NSQHS Standards: 1  Governance, 9  Clinical Deterioration		

**Printed or personally saved electronic copies of this document are considered uncontrolled.
Access the current version from the WNHS website.**